Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NISCH | Q9Y2I1 | 8/20 | 0.82 |
| ▸ | MAOA | P21397 | 6/20 | 0.66 |
| ▸ | MAOB | P27338 | 6/20 | 0.66 |
| ▸ | TAAR1 | Q96RJ0 | 4/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.49 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.49 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.49 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.49 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.49 |
| ▸ | HTR1D | P28221 | 2/20 | 0.47 |
| ▸ | HTR1B | P28222 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7547171 | 0.91 | NISCH (1.00) | NISCHMAOAMAOBTAAR1LMNA | |
| SCHEMBL7550483 | 0.87 | NISCH (0.75) | NISCHMAOAMAOBTAAR1LMNA | |
| SCHEMBL7548077 | 0.85 | NISCH (0.82) | NISCHMAOAMAOBTAAR1LMNA | |
| SCHEMBL7553404 | 0.84 | NISCH (0.87) | NISCHMAOAMAOBTAAR1LMNA | |
| SCHEMBL7551706 | 0.81 | NISCH (0.81) | NISCHMAOAMAOBTAAR1LMNA | |
| Hydrochloric Acid SCHEMBL11550188 | 0.80 | NISCH (0.78) | NISCHMAOAMAOBTAAR1LMNA | |
| SCHEMBL11554305 | 0.80 | NISCH (0.78) | NISCHMAOAMAOBTAAR1LMNA | |
| SCHEMBL17886837 | 0.80 | NISCH (1.00) | NISCHMAOAMAOBTAAR1LMNA | |
| SCHEMBL17887935 | 0.80 | NISCH (1.00) | NISCHMAOAMAOBTAAR1LMNA | |
| SCHEMBL17886753 | 0.80 | NISCH (1.00) | NISCHMAOAMAOBTAAR1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2002038559-A1 | 1,3-DIAZAHETEROCYCLIC COMPOUNDS AND THEIR USE AS ORAL HYPOGLYCAEMIC AGENTS | NOVO NORDISK A/S (DK) | 2002-05-16 | — | — | WO | claimed |
| US-20020132812-A1 | Oral hypoglycaemic agents | NOVO NORDISK A/S (DK) | 2002-09-19 | — | — | US | disclosed |
| WO-2002038559-A1 | 1,3-DIAZAHETEROCYCLIC COMPOUNDS AND THEIR USE AS ORAL HYPOGLYCAEMIC AGENTS | NOVO NORDISK A/S (DK) | 2002-05-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020132812-A1 | Oral hypoglycaemic agents | SLC5A2, GPR119, SLC5A1 | NISCH 448/4885MAOA 3214/4885MAOB 2627/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.